Search Results
Your search for this matches 25363 pages
Showing 16401 - 16450Does Adding Bortezomib to Lenalidomide/Dexamethasone Improve Outcomes in Patients With Newly Diagnosed Myeloma?
In the phase III SWOG S0777 trial reported in The Lancet, Durie et al found that adding bortezomib (Velcade) to lenalidomide (Revlimid)/dexamethasone improved progression-free and overall survival in patients with newly diagnosed myeloma who were not planned for immediate autologous stem cell...
NCI-Designated Cancer Centers Issue Statement in Support of New CDC Recommendations on HPV Vaccination
The 69 National Cancer Institute (NCI)-designated cancer centers have issued a joint statement in support of recently revised recommendations from the Centers for Disease Control and Prevention (CDC) to improve national vaccination rates for human papillomavirus (HPV). According to the CDC,...
Older Patients With Lung Cancer Face Significant Treatment Burden
Depending on the type of treatment older patients with lung cancer receive, they can spend an average of 1 in 3 days interacting with the health-care system in the first 60 days after surgery or radiation therapy, according to a study by Yale researchers. These findings were published by Presley in ...
Disappointing Efficacy of Chemotherapy Guided by Ki67 Level After Neoadjuvant AI Therapy for Breast Cancer
In an analysis in the American College of Surgeons Oncology Group (ACOSOG) Z1031 Trial/Alliance reported in the Journal of Clinical Oncology, Ellis et al found that switching to chemotherapy in patients with elevated Ki67 levels after 2 to 4 weeks of neoadjuvant aromatase inhibitor therapy resulted ...
Results of International Cross-Sectional Survey Reveal Gaps in Primary and Secondary Skin Cancer Prevention, Perceptions, and Knowledge
A large international survey on sun exposure behaviors and skin cancer detection found there are many imperfections and geographic disparities in primary and secondary prevention of skin cancer. This information could help inform future awareness campaigns developed to address the global need to...
ASCO Clinical Practice Guideline Update: Integration of Palliative Care Into Standard Oncology Care
As reported by Betty R. Ferrell, PhD, of the City of Hope Medical Center, and colleagues in the Journal of Clinical Oncology, ASCO has released a clinical practice guideline update on the integration of palliative care into standard oncology care. This update of a 2012 ASCO provisional clinical...
ACCC 2016 Survey Finds Cancer Drug Costs Remain the Most Critical Challenge to Care
As more cost pressures are placed on the health-care system, and the transition to value-based care gains momentum, the Association of Community Cancer Centers’ (ACCC) 7th annual Trends in Cancer Programs survey revealed critical challenges and emerging trends in U.S. cancer programs. The...
Receptor Tyrosine Kinase AXL May Mediate Nuclear Translocation of EGFR
New research from the University of Wisconsin (UW) Carbone Cancer Center has clarified the mechanisms involved in a common growth pathway implicated in many solid tumor types and could lead to better outcomes for patients with head and neck, lung, and triple-negative breast cancer,...
Endometrial Cancer Mutations May Be Detectable in Uterine Lavage Fluid Before Cancer Is Diagnosed
Mutations that have been linked to endometrial cancer can be found in the uterine lavage fluid of pre- and postmenopausal women both with and without detectable cancer, according to a study published by Nair et al in PLOS Medicine. “Today, there are no effective screening methods for...
Contralateral Prophylactic Mastectomy Decisions in a Population-Based Sample of Patients With Early-Stage Breast Cancer
In a new study published by Jagsi et al in JAMA Surgery, nearly half of patients with early-stage breast cancer considered having double mastectomy, and one in six received it—including many who were at low risk of developing a second breast cancer. Many patients who chose double...
Preclinical Study Potentially Explains Vulnerability of Young Patients With Cancer to Treatment Toxicities
Despite many successes in treating pediatric cancer, young children remain at high risk for developing severe, long-lasting impairments in their brain, heart, and other vital organs from chemotherapy and radiation treatments. In adults, however, these tissues are relatively spared. This disparity, ...
Vascular-Targeted Photodynamic Therapy Shows Promise in Low-Risk Prostate Cancer
In a European phase III trial reported in The Lancet Oncology, Azzouzi et al found that padeliporfin vascular-targeted photodynamic therapy was associated with a reduced rate of disease progression vs active surveillance in men with low-risk prostate cancer. Study Details In the open-label trial, ...
Myeloid-Derived Suppressor Cells May Enable Tumor Cells to Circumvent Immune Attack, Improving Immunotherapy
One of the main reasons cancer remains difficult to treat is that cancer cells have developed a multitude of mechanisms that allow them to evade destruction by the immune system. One of these escape mechanisms involves a type of immune cell called myeloid-derived suppressor cells (MDSCs). A recent...
Use of Genetic Testing to Identify Patients With Breast Cancer at High Risk for Venous Thromboembolism
Venous thromboembolism is a serious—and sometimes fatal—complication of cancer and chemotherapy treatment. Since breast cancer is one of the most common cancers, it accounts for a large number of cancer-related cases of venous thromboembolism. Routine thromboprophylaxis, however, is not recommended ...
Osimertinib Shows Activity in Pretreated EGFR Thr790Met–Positive Advanced NSCLC
In a phase II trial reported in The Lancet Oncology, Glenwood Goss, MD, of The Ottawa Hospital Cancer Centre, University of Ottawa, and colleagues found that osimertinib produced a high response rate in EGFR tyrosine kinase inhibitor–pretreated EGFR Thr790Met (T790M)–positive advanced non–small...
Colonoscopy Screening in Older Adults
A large population-based observational study by Xabier García-Albéniz, MD, PhD, of the Harvard T.H. Chan School of Public Health, and colleagues evaluating the effectiveness and safety of screening colonoscopy for the prevention of colorectal cancer in people aged 70 to 74 and 75 to 79 has found...
R. Daniel Beauchamp, MD, Receives 2016 Dr. Rodman E. and Thomas G. Sheen Award
R. Daniel Beauchamp, MD, Chair of the Section of Surgical Sciences and the John Clinton Foshee Distinguished Professor of Surgery at the Vanderbilt-Ingram Cancer Center, has been selected to receive the 2016 Dr. Rodman E. and Thomas G. Sheen Award from the New Jersey American College of Surgeons...
Expect Questions About Screening Mammography for Women Aged 75 Years and Older
A study finding that there is no clear cutoff age to stop breast cancer screening has received national coverage in newspapers and CNN as well as in health and medical publications. “I am glad this is catching fire, because it really needs to be out there,” Cindy S. Lee, MD, the study’s lead...
Study Suggests No Evidence for Screening Mammography Cutoff Age
An analysis of data from nearly 6 million screening mammograms found no evidence for a clear cutoff age to stop breast cancer screening. Screening mammography among women aged 75 years was associated with higher cancer detection and lower recall rates than among younger women in the study. These...
AbbVie and Lurie Cancer Center, Johns Hopkins Announce 5-Year Oncology Research Collaborations
The global biopharmaceutical company AbbVie has announced collaborations with the Robert H. Lurie Comprehensive Cancer Center of Northwestern University and Johns Hopkins University School of Medicine. These 5-year partnerships to advance cancer research and discovery in oncology will focus on...
Exploring Practical Strategies for Cancer Care in Low-Resource Settings
One of the featured “Big Debates” at the 2016 World Cancer Congress in Paris addressed this question: Are scarce resources best applied to prevention rather than treatment? Many experts do not see prevention vs treatment in such stark terms or even as a realistic scenario. It’s a false dichotomy,...
Co-occurrence of Cancer and Cognitive Impairment in Older Adults
The prevalence of both cancer and cognitive impairment increases with age.1-3 Based upon Surveillance, Epidemiology, and End Results (SEER)-Medicare studies, it is estimated that 3% to 7% of patients with cancer aged ≥ 65 also suffer from dementia, although the true prevalence of dementia in this...
The Best of SIO
The following five abstracts were chosen as the best submitted studies presented at this year’s International Conference of the Society for Integrative Oncology (SIO). They represent a diverse group of integrative therapies and interventions in the care of patients with cancer, including an...
Advancing the Global Impact of Integrative Oncology
The 13th International Conference of the Society of Integrative Oncology (SIO) held in Miami, Florida, in November, drew its largest audience yet, with nearly 400 clinicians, researchers, patients, and patient advocates in integrative oncology care from 25 countries in attendance with large...
Expert Point of View: Carlos L. Arteaga, MD
Press conference moderator Carlos L. Arteaga, MD, of Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, said that buparlisib will probably not be clinically useful, partly because it crosses the blood-brain barrier , thus causing mood disorders, and is not an ideal phosphoinositide 3-kinase...
Buparlisib Phase III Findings: Glass Half Empty or Half Full?
The pan-phosphoinositide 3-kinase (PI3K) inhibitor buparlisib combined with fulvestrant (Faslodex) prolonged progression-free survival compared with placebo and fulvestrant in postmenopausal women with hormone receptor–positive, HER2-negative advanced breast cancer previously treated with an...
Expert Point of View: Myles Brown, MD, Carlos L. Arteaga, MD, and Eric Winer, MD
Myles Brown, MD, Director of the Center for Functional Cancer Epigenetics at Dana-Farber Cancer Institute, Boston, suggested the failure of the endocrine therapy to increase the pathologic complete response rates “may be related to the fact that the aromatase inhibitor was not the optimal...
Pathologic Complete Response Not Boosted by Addition of Estrogen Deprivation to Chemotherapy and Dual HER2 Blockade
The addition of estrogen deprivation to neoadjuvant chemotherapy and HER2 blockade did not enhance the achievement of pathologic complete responses in women with early-stage breast cancer, according to the results of the NRG Oncology/NSABP B-52 trial reported at the 2016 San Antonio Breast Cancer...
Expert Point of View: Carlos L. Arteaga, MD
Press conference moderator Carlos L. Arteaga, MD, said: “This drug is not necessarily the same as palbociclib [Ibrance] or ribociclib. There are subtle differences among these three [cyclin-dependent kinase (CDK) 4/6] inhibitors. The tissue analysis provides us with an enormous opportunity to...
Abemaciclib Plus Anastrozole: Promising Signals Reported in Phase II Study of Early Breast Cancer
As neoadjuvant therapy, abemaciclib alone or in combination with anastrozole achieved strong signals of anticancer activity in postmenopausal patients with hormone receptor–positive, HER2-negative breast cancer in the neoMONARCH phase II study.1 Abemaciclib alone or in combination with anastrozole...
Expert Point of View: Leif Ellisen, MD, PhD
Results of this trial have been anticipated for a long time. Women were enrolled between 2000 and 2008,” said Leif Ellisen, MD, PhD, Program Director of Breast Medical Oncology at Massachusetts General Hospital Cancer Center in Boston. Regarding the survival advantage in triple-negative...
BRCA Status Does Not Seem to Affect Survival Outcomes in Young Women With Early Breast Cancer
Young women who carry the BRCA1 and/or BRCA2 mutation and develop breast cancer seem to have similar survival compared with young women who have BRCA-negative breast cancer. However, women with BRCA-positive triple-negative breast cancer have an 11% survival advantage compared with those with...
Genomic Landscape of Metastatic Breast Cancer Differs From That of Primary Breast Cancer
Researchers working on whole-exome and transciptome sequencing of endocrine-resistant estrogen receptor–positive metastatic breast cancer have shown that the mutational landscape differs from that of estrogen receptor–positive primary breast cancer, and these differences have the potential to...
Expert Point of View: Virginia Kaklamani, MD
How can the results of this trial be applied to clinical practice? Press conference moderator, Virginia Kaklamani, MD, of the University of Texas Health Science Center in San Antonio, said: “The landscape has changed. Now we treat postmenopausal hormone receptor–positive, HER2-negative metastatic...
Fulvestrant Plus Everolimus: New Second-Line Option for Postmenopausal Metastatic Breast Cancer
The addition of everolimus (Afinitor) to fulvestrant (Faslodex) doubled progression-free survival in postmenopausal women with hormone receptor–positive, HER2-negative metastatic breast cancer resistant to aromatase inhibitor therapy compared with fulvestrant plus placebo, according to the...
Oncology Organizations Applaud Passage of the 21st Century Cures Act
On Tuesday, December 13, President Obama signed into law the 21st Century Cures Act, landmark legislation designed to improve and accelerate the pace of biomedical research in the United States. ASCO Chief Executive Officer Clifford Hudis, MD, FACP, FASCO, attended the White House signing ceremony ...
Gilberto de Lima Lopes, Jr, MD, MBA, FAMS, Named New Editor-in-Chief of ASCO’s Journal of Global Oncology
ASCO announced that Gilberto de Lima Lopes, Jr, MD, MBA, FAMS, will become Editor-in-Chief of the Society’s Journal of Global Oncology (JGO) in early 2017. Dr. Lopes will direct the editorial scope of JGO, an online-only, open-access journal addressing the unique challenges of cancer care and...
FDA Permits Marketing of New Tissue Expander for Women Undergoing Breast Reconstruction Following Mastectomy
On December 21, the U.S. Food and Drug Administration (FDA) allowed marketing of a new tissue-expander system for soft-tissue expansion in two-stage breast reconstruction following mastectomy and in the treatment of underdeveloped breasts and soft-tissue deformities. A patient uses a dose...
Expert Point of View: Armand Keating, MD
“This study shows that a great deal of innovation can come from existing knowledge. The 7+3 regimen has been around since I was an intern,” admitted Armand Keating, MD, of the University of Toronto and Princess Margaret Hospital, Toronto, Ontario, Canada. “Using the liposomal formulation of...
CPX-351 Improves Survival Post Transplant in Older High-Risk Patients With Acute Myeloid Leukemia
Induction therapy with the experimental chemotherapy called CPX-351—a liposomal formulation of cytarabine and daunorubicin—outperformed standard “7+3” cytarabine plus daunorubicin by extending survival in older high-risk patients with acute myeloid leukemia (AML) who subsequently underwent...
Expert Point of View: Mikkael A. Sekeres, MD, MS
Mikkael A. Sekeres, MD, MS, Director of the Leukemia Program at the Cleveland Clinic Taussig Cancer Center in Ohio, commented on vadastuximab talirine in newly diagnosed acute myeloid leukemia (AML). He noted that the drug is similar to gemtuzumab ozogamicin, another antibody-drug conjugate that...
Vadastuximab Talirine Shows Early Promise in Newly Diagnosed Acute Myeloid Leukemia
The investigational CD33-directed antibody-drug conjugate vadastuximab talirine yielded high overall and complete response rates when combined with standard “7+3” chemotherapy for patients newly diagnosed with acute myeloid leukemia.1 Results from this phase Ib study were presented at the 2016...
A Lesson From David
The following essay by Jeremy K. Hon, MD, is adapted from The Big Casino: America’s Best Cancer Doctors Share Their Most Powerful Stories, which was coedited by Stan Winokur, MD, and Vincent Coppola and published in May 2014. The book is available on Amazon.com and thebigcasino.org. As physicians, ...
2017 Oncology Meetings
JANUARY 2017 2017 Oncologic Emergency Medicine ConferenceJanuary 12-13 • Houston, Texas For more information: www.mdanderson.org/education-training/professional-education/cme-conference-management/conferences/oncologic-emergency-medicine-conference.html 2017 Highlights of ASH in North...
Expert Point of View: Lawrence Kaplan, MD
“This study is important because R-CHOP [rituximab and cyclophosphamide, doxorubicin, vincristine, prednisone] has been the standard of care for many years. CHOP, the chemotherapy backbone, has withstood challenges from more aggressive regimens in the past. The excellent clinical outcomes observed ...
St. Jude Names Ellis J. Neufeld, MD, PhD, Clinical Director, Physician-in-Chief, and Executive Vice President
Ellis J. Neufeld, MD, PhD, has been appointed Clinical Director, Physician-in-Chief, and Executive Vice President of St. Jude Children’s Research Hospital. Dr. Neufeld’s appointment will begin in March 2017. In this role, Dr. Neufeld will oversee the organization’s academic clinical departments...
Weighing the Benefits and Risks of Medical Marijuana
Despite the fact that 28 states and the District of Columbia have enacted laws to permit the use of cannabis and cannabinoid-based drugs to treat medical conditions, including cancer and symptoms from its treatment, federal law prohibits physicians from prescribing marijuana to their patients,...
Dose-Adjusted EPOCH-R No Better Than R-CHOP in Diffuse Large B-Cell Lymphoma
Long-awaited results of the Cancer and Leukemia Group B (CALGB)/Alliance 50303 trial were a disappointment to many hematologists/oncologists at the 2016 American Society of Hematology (ASH) Annual Meeting & Exposition. The study failed to show that dose-adjusted EPOCH-R (etoposide,...
Accelerating Progress in the Treatment of Glioblastoma Multiforme
W.K. Alfred Yung, MD, has wanted a career in medicine since he was a high-school student and has spent nearly 4 decades fulfilling that dream, specifically in the research and treatment of one of the deadliest cancers, malignant brain tumor, especially glioblastoma multiforme, the most common...
Expert Point of View: Brad S. Kahl, MD
Speaking about the GALLIUM study in the ASH News Daily, Brad S. Kahl, MD, of Washington University School of Medicine, St. Louis, commented, “It is a potentially practice-changing study that clearly shows an 8% absolute improvement in progression-free survival at 2 years for the patients getting...
